FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

KRS 315.0351 requires out-of-state pharmacies doing business in Kentucky, including by mail, internet or phone, to hold a current Kentucky pharmacy permit. They must submit the most recent inspection report from their home-state regulator, and later reports as they are issued. They must have 'a pharmacist in charge who is licensed to engage in the practice of pharmacy by the Commonwealth,' and must provide a toll-free line to the pharmacist in charge at least 6 days and 40 hours a week, printed on containers. 201 KAR 2:465 (effective 2025-02-05) requires a record of a satisfactory inspection within the previous 24 months by the home-state licensing entity, or by a Board-recognized third party if no state inspection is available. It also requires anyone practicing pharmacy for a Kentucky resident to hold a Kentucky pharmacist license, unless the Board waives this for 'isolated transactions' (no more than 3 dispensings a year to an established patient). The Board's application list asks for the home-state permit, last inspection report, DEA registration, license verification, a 7-day end-of-day report and a signed Memorandum of Understanding and Agreement. The fee is $150 and the permit expires each June 30. The Kentucky Board of Pharmacy enforces these rules.

201 KAR 2:465 took effect 2025-02-05 (a 2025 change) and expires 2032-02-05. The KRS text was read from FindLaw (marked current as of 2025-01-01) because the official KRS site serves sections by numeric ID; the Board page confirms the statute and the Kentucky-licensed PIC requirement.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

KRS 315.010(6) defines compounding as preparing a drug 'pursuant to or in anticipation of a valid prescription drug order.' KRS 315.010(14) defines a 'medical order' as an order 'for a specifically identified patient.' 201 KAR 2:076 Section 5(1) requires a prescription or medical order from a prescriber before any compounded sterile or non-sterile preparation is dispensed. The rule has no office-use or non-patient-specific provision for human drugs. Kentucky separately licenses 503B outsourcing facilities, which by definition compound without patient-specific prescriptions (KRS 315.010(16); 201 KAR 2:400). This matches FDA's view that 503A compounding needs patient-specific prescriptions. The Kentucky Board of Pharmacy enforces these rules.

No express office-use prohibition was found. This answer rests on the patient-specific definitions and the absence of any office-use authorization. The Board's general FAQ lets a pharmacy sell prescription medications to practitioners for office use within a 5% limit (citing KRS 315.400 and the federal Drug Supply Chain Security Act, DSCSA), but it does not mention compounded preparations; check with the Board. 201 KAR 2:076 was amended effective 2023-10-25, and the Board began enforcing the 2022 USP <795>/<797> revisions on 2026-01-01. The Board issued GLP-1 compounding guidance in 2025 and a 'Compliance Alert - Compounded GLP-1/GIP' on 2025-11-14 (https://pharmacy.ky.gov/Documents/Compound%20Compliance%20Alert%20GLP1_GIP%2011.14.2025%281%29.pdf, linked but not read in full). Kentucky did sign FDA's 2020 standard MOU (MOU 225-21-012, effective 2021-09-10, per FDA's Compounding MOUs page); see the fda_mou topic. FDA's page, current as of 2026-08-28, says it considers that MOU suspended and does not expect signatory states to carry it out (https://www.fda.gov/drugs/human-drug-compounding/memorandum-understanding-addressing-certain-distributions-compounded-drugs).

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

The Kentucky Board of Pharmacy says an Outsourcer Facility license is required under KRS 315.340 and 315.342. 201 KAR 2:400 sets licensure requirements for in-state and out-of-state outsourcing facilities: a $250 fee, a sworn and notarized application, proof of FDA 503B registration, and a copy of the current FDA inspection report (or an NABP or Board-agent inspection if no FDA report is available). The Board's page also asks nonresident facilities for their home-state outsourcer license, DEA registration if any, most recent inspection, license verification and disciplinary history. It says a Kentucky-licensed pharmacist in charge is required, citing 201 KAR 2:400 and 201 KAR 2:205. Licenses expire each June 30. The Kentucky Board of Pharmacy enforces these rules.

201 KAR 2:400 took effect 2018-01-18 and was recertified 2024-12-02 (expires 2031-12-02). The rule asks for the 'current' FDA inspection report without a set time limit. The Board has also published 'Guidance for Kentucky Pharmacies Acquiring Human Compounded Products from 503B Outsourcing Facilities' (https://pharmacy.ky.gov/Documents/Declaratory%20Opinion_Aquring%20503B%20Compounds%20for%20Dispensing.pdf, not read in full).

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. The Kentucky Board of Pharmacy signed MOU 225-21-012, effective September 10, 2021; Kentucky is one of only three signatories (with Colorado and New Hampshire). FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

The Kentucky Board of Medical Licensure advises that before procuring, dispensing or prescribing controlled substances to Kentucky patients a physician must have an active Kentucky medical license, a DEA registration number specific to Kentucky, and an active KASPER account; practitioners storing controlled substances at multiple Kentucky locations may need additional DEA registrations. KRS 218A.202 requires every practitioner authorized to prescribe or dispense controlled substances to register with and maintain a KASPER account. KRS chapter 218A contains no practitioner CS registration (the former licensing section 218A.150 was repealed in 2018).

Kentucky pain-management facility rules (KRS 218A.175) apply separately. APRNs and PAs follow their own boards' CS prescribing rules plus DEA (not verified here).

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

201 KAR 9:260 (Kentucky Board of Medical Licensure, covering physicians and PAs) requires a licensee, before initially prescribing, dispensing or administering a controlled substance for pain (Section 3) or for any other condition (Section 7(1)), to obtain and review a KASPER report covering the prior 12 months. For controlled substances used for pain beyond 3 months, a new KASPER report is required at least every three months, and immediately if diversion or misuse is suspected. Exemptions include hospice/end-of-life care, hospital inpatient/outpatient/observation care, cancer pain, long-term-care residents, disasters, a single dose for a test or procedure, Schedule V drugs, research subjects, substitutions within 7 days, repeat prescribing within 90 days by a colleague in the same practice for the same condition, and use within 14 days of major surgery or significant trauma. Violations are disciplined by the Board.

Source older than 2 years - possibly stale (last amended eff. 11/19/2020 per the regulation history; read on the official LRC site 2026-09-23). Frequency for testosterone: before the initial prescription/dispensing/administration; periodic 3-month checks are explicitly required for long-term pain treatment. The rule covers administering and dispensing, so in-office testosterone is caught unless an exemption applies. Other boards have their own rules (e.g., 201 KAR 20:057 for APRNs) and the statute KRS 218A.172 was not opened - scope for non-physician prescribers may differ.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

201 KAR 9:260 sets professional standards for prescribing, dispensing and administering controlled substances, including documentation and a general limit of a three-day supply of Schedule II drugs for acute pain. A vendor summary reports that no separate dispensing license is required, that dispensing may not be delegated to PAs, NPs or staff, and that dispensed controlled substances must be reported to KASPER by the next business day.

Absence of a dispensing license is from a vendor summary; confirm with the Kentucky Board of Medical Licensure.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Kentucky law bars state agencies from requiring in-person contact unless the provider finds it medically necessary (KRS 211.336). For controlled-substance purposes, the 'good-faith prior examination' may include telehealth examinations (KRS 218A.010(18)). The medical board notes that questionnaire-based online or telephone evaluations are inadequate for initial or follow-up evaluations (KRS 311.597(1)). No Kentucky telehealth-specific Schedule III limit was found beyond the board's controlled-substance standards. IMLC: member.

Kentucky's 201 KAR 9:260 controlled-substance standards (e.g. PDMP review before initial prescribing) also apply.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

KBN Advisory Opinion Statement #35 (revised June 2026) classes neuromodulators and dermal fillers as Level III advanced aesthetic procedures that require specific training and competence, 'supervision' for RNs (provider on the premises or readily available by phone) and 'direct supervision' for LPNs by a qualified, appropriately trained provider. Procedures may be performed only after a qualified provider (MD, APRN, PA or dentist) documents an initial assessment and treatment plan; RNs may then use the provider's standing orders or protocols. The AOS states it is not within RN or LPN scope to independently practise, order products, prescribe treatments or perform medical aesthetic procedures such as Botox or dermal fillers, and it recommends on-site supervision of novice injectors.

Revised June 2026 (month only). The AOS's procedure chart uses graphic check marks that could not be extracted as text, and its sentence on Botox/fillers can be read as barring RN injection altogether; the reading above follows the Level III definition, which provides for RN supervision. Confirm with KBN before relying on it.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The March 2025 joint statement of the Kentucky Boards of Medical Licensure, Nursing and Pharmacy says an APRN (or other prescriber) must establish a practitioner-patient relationship and do a good-faith prior examination before ordering IV therapy; RNs may do ongoing assessments using a prescriber-approved standardized review document within protocols or standing orders; and prescribing, compounding and administration may not be delegated to unlicensed persons. RNs, LPNs and EMTs may not possess or store legend drugs, including overnight in a home or vehicle, which constrains mobile services. KBN AOS #35 (June 2026) adds that IV clinics, mobile or freestanding, are not specifically regulated, that IV fluid always needs a qualified provider's order, and that nurses may add no more than two sterile products to a bag, administered within four hours.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Kentucky as 'Moderate (Relaxed)', citing KRS 311.560 and Kentucky Board of Medical Licensure Opinion No. 36 (1995). MedPath Compliance (reviewed 2026-06-20) lists Kentucky as a CPOM state that is lightly enforced. The 2025 joint IV statement separately stresses that businesses may not have unlicensed people practise medicine.

Statute and board opinion text not fetched.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

KBN AOS #35 lists non-ablative laser for hair removal only, non-ablative laser treatment of skin and pulsed light therapy as Level II procedures that must be ordered by an authorized prescriber as part of a medical plan of care, after a documented initial assessment by a qualified provider. Ablative laser is listed among medical procedures not within RN or LPN scope (nurses may assist). The AOS recommends a laser physics and safety course. No Kentucky laser-technician licence was found.

Covers nurses only; Kentucky Board of Medical Licensure rules on delegating lasers to other staff were not located.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Kentucky was not among them, but this research did not confirm its statutes. Kentucky's CLIA state agency is Kentucky CLIA Program, Office of Inspector General (KYCLIALabinquiries@ky.gov, 502-564-7963); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Kentucky's rule. Kentucky's lab regulator (CLIA state agency) is Kentucky CLIA Program, Office of Inspector General (KYCLIALabinquiries@ky.gov, 502-564-7963). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Kentucky is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Kentucky does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.